CitizenMerck Isn't Down For The Count, But The Punches Keep Coming
CNNMoney.com - 2 hours ago
Merck & Co.'s (MRK) failure to win US regulatory approval for a new cholesterol drug doesn't leave the drug maker down for the count, but it could make it harder to roll with the punches of generic competition in coming years.
UPDATE 1-Cholesterol-drug rejection rips new gash in Merck Reuters
Merck's Recovery Flushed Down Motley Fool
The Associated Press  - Houston Chronicle  - MarketWatch  - Forbes
all 337 news articles